FGF23 and hypophosphatemia: Conventional therapy of HR includes oral phosphate supplementation and, in forms with FGF23-mediated hypophosphatemia, calcitriol; however, this therapy further stimulates FGF23 excretion, enforcing the renal phosphate wasting (6).